New drugs aim to slow muscle decline in duchenne muscular dystrophy
NCT ID NCT07682129
First seen Jul 02, 2026 · Last updated Jul 02, 2026
Summary
This study tests two experimental drugs, ENTR-601-44 and ENTR-601-45, in people with Duchenne muscular dystrophy (DMD) who have already taken part in earlier studies. The goal is to see if long-term use is safe and tolerable, and whether it can help maintain muscle function. Participants receive regular intravenous infusions and undergo tests like blood work, physical exams, and muscle biopsies. The study also tracks changes in walking speed and other physical abilities over time.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ENTR-601-44 and ENTR-601-45 (intravenous infusions)
What this could lead to
If successful, this could show that long-term treatment with these drugs is safe and may help preserve muscle function in people with Duchenne muscular dystrophy.
What could go wrong
This is an early-phase extension study, so it is small and not designed to prove effectiveness. The drugs may cause side effects or not work as hoped.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DUCHENNE MUSCULAR DYSTROPHY (DMD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- DMD Heart Function Study Using MRI (NCT07674758)
- Digital Monitoring for Upper Limb Function in DM NCT07664124
- GLP-1 Drug Safety in Duchenne Muscular Dystrophy NCT07642635
- DYNE-251 for Duchenne Muscular Dystrophy (NCT07608432)
- Duchenne EHR Study: Better Data for Better Care NCT07609394
- Virtual Reality for DMD Upper Limb Function – NCT07039799
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Alder Hey Children's NHS Foundation Trust
Liverpool, L122AP, United Kingdom
-
Centre Hospitalier Régional de la Citadelle
Liège, 4000, Belgium
-
Fondazione Policlinico Universitario A. Gemelli IRCCS - Universita Cattolica del Sacro Cuore
Roma, 00168, Italy
-
Fondazione Serena Onlus - Centro Clinico NeMO Milano
Milan, 20162, Italy
-
Freeman Hospital
Newcastle upon Tyne, NE1 3BZ, United Kingdom
-
Great Ormond Street Hospital for Children
London, WC1N 3JH, United Kingdom
-
Hospital Sant Joan de Deu
Barcelona, 08950, Spain
-
Hospital Universitario Vall d'Hebron
Barcelona, 08035, Spain
-
IRCCS Ospedale San Raffaele
Milan, 20132, Italy
-
Leeds General Infirmary
Leeds, LS1 3EX, United Kingdom
-
Leids Universitair Medisch Centrum
Leiden, 2333 ZA, Netherlands
-
Ospedale Pediatrico Bambino Gesu
Rome, 00165, Italy
-
Oxford University Hospitals NHS Foundation Trust
Oxford, OX3 9DU, United Kingdom
-
Royal Manchester Children's Hospital
Manchester, M13 9WL, United Kingdom
-
Stichting Radboud Universitair Medisch Centrum
Nijmegen, 6525 GA, Netherlands
-
UZ Leuven
Leuven, 3000, Belgium
-
University Hospital Gent
Ghent, 9000, Belgium